Quel est le prix pour Novo Nordisk A/S (NOVO-B)

Le prix pour Novo Nordisk A/S (NOVO-B) est $43.92

Quelle est la capitalisation boursière pour Novo Nordisk A/S (NOVO-B)

La capitalisation boursière pour Novo Nordisk A/S (NOVO-B) est $195.10B

Novo Nordisk A/S (NOVO-B) Ratio P/S

Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

Année	Ratio P/S	Changez
Pas assez de données pour les dates fournies.

Année

Ratio P/S

Changez

Pas assez de données pour les dates fournies.

Entreprise	Ratio P/S	Différence de Ratio P/S	Pays
Eli Lilly and Company LLY.US	13.69	206.53%	US
Johnson & Johnson JNJ.US	6.54	46.52%	US
AbbVie Inc. ABBV.US	7.04	57.56%	US
Roche Holding AG RO.SW	4.66	4.33%	CH
Merck & Co., Inc. MRK.US	5.50	23.09%	US

Entreprise

Ratio P/S

Différence de Ratio P/S

Pays

Eli Lilly and Company

LLY.US

13.69

206.53%

Johnson & Johnson

JNJ.US

6.54

46.52%

AbbVie Inc.

ABBV.US

7.04

57.56%

Roche Holding AG

RO.SW

4.66

4.33%

Merck & Co., Inc.

MRK.US

5.50

23.09%

Novo Nordisk A/S

NOVO-B

Catégorie